LAVAL, Quebec, Nov. 9, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that the Company will provide a business update for investors on a conference call to be held Tuesday, November 10, 2015 at 8:00 a.m. ET.
J. Michael Pearson, Chairman and Chief Executive Officer, together with Robert Rosiello, Chief Financial Officer, Dr. Ari Kellen, Company Group Chairman, Deb Jorn, Company Group Chairman and Tanya Carro, Corporate Controller, will conduct the call.
The conference call on November 10 will consist of an overview of current plans and priorities, including the transition plan from Philidor, and an update on the Company's operations. Immediately thereafter, there will be a question and answer segment for investors and analysts.
Valeant intends to host an Investor Day and update its annual and quarterly financial guidance prior to the end of 2015.
Conference Call Information
The Company will host a conference call at 8:00 a.m. ET (5:00 a.m. PT), November 10, 2015 to provide a business update. The dial-in number to participate on this call is (877) 876-8393 confirmation code 78262163. International callers should dial (973) 200-3961, confirmation code 78262163. A replay will be available approximately two hours following the conclusion of the conference call through November 17, 2015 and can be accessed by dialing (855) 859-2056, or (404) 537-3406, confirmation code 78262163.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
This press release may contain forward-looking statements, including, but not limited to, statements regarding Valeant's intent to hold an Investor Day and to issue annual and quarterly financial guidance by year end. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.
Laurie W. Little
Renee E. Soto/Meghan Gavigan
Sard Verbinnen & Co.
firstname.lastname@example.org / email@example.com
Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-to-hold-conference-call-for-investors-to-provide-business-update-300174622.html
SOURCE Valeant Pharmaceuticals International, Inc.